Human Papilloma Virus Flashcards

1
Q

What are the oncogenic HPV types associated with cervical cancer?

A

HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59

HPV68 is considered probably oncogenic.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What percentage of cervical cancers is attributed to HPV16?

A

Approximately 53% to 73%

HPV18 accounts for another 12% to 21%.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the relationship between HPV infection and cervical cancer?

A

HPV infection is the major risk factor for cervical cancer development.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How much higher is the rate of cervical cancer in women with HIV compared to the general population?

A

3 to 4 times higher

95% confidence interval [CI], 3.13–3.70.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What factors increase the relative risk of cervical cancer in women with HIV?

A

Decreasing CD4 T lymphocyte (CD4) cell counts.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the incidence rate of invasive cervical cancer (ICC) in women with HIV?

A

47.7 per 100,000 person-years.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the significance of CD4 counts in relation to anal cancer risk in people with HIV?

A

Low CD4 counts are associated with increased risk of anal cancer.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the cumulative 4-year progression from high-grade squamous intraepithelial lesion (HSIL) to anal cancer estimated in the ANCHOR study?

A

1.8%.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What types of HPV are responsible for the majority of anogenital warts?

A

Non-oncogenic HPV types 6 or 11.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the principal clinical manifestations of mucosal HPV infection?

A

Genital, anal, and oral warts; CIN; VIN; VAIN; AIN; anogenital squamous cell cancers; cervical adenocarcinomas.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the recommended age for routine HPV vaccination?

A

Age 11 or 12 years.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How many doses of the 9-valent HPV vaccine are recommended for people with HIV?

A

Three doses.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Is HPV vaccination recommended during pregnancy?

A

No.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the main purpose of the HPV vaccine?

A

To prevent HPV infection.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the FDA-approved HPV vaccines available in the U.S.?

A

Bivalent, quadrivalent, and 9-valent.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the indication for the 9-valent HPV vaccine?

A

Prevention of cervical, vaginal, vulvar, and anal cancer; genital warts; oropharyngeal and other head and neck cancers.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is the significance of shared clinical decision-making regarding HPV vaccination for adults aged 27 to 45 years?

A

It is recommended for those not adequately vaccinated and at risk for new HPV infection.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What did studies show about the immune response to HPV vaccination in people with HIV?

A

Immune responses appear stronger among those with higher CD4 counts and suppressed HIV viral loads.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What type of lesions may indicate a higher risk for anal cancer in people with HIV?

A

High-grade anal intraepithelial neoplasia (AIN).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

True or False: HPV vaccination prevents all HPV types that may lead to cervical cancer.

A

False.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is the relationship between ART and the incidence of HPV and CIN?

A

Effective ART use is associated with decreased incidence, persistence, and progression of HPV and CIN.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is the incidence rate of HIV among youth who acquired it perinatally?

A

100 person-years of 15 (10.9–29.6)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is the incidence rate of HIV among youth who were exposed but uninfected?

A

100 person-years of 2.9 (0.4–22.3)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What is the recommendation for people with HIV who have been vaccinated regarding cervical cancer screening?

A

Continue routine cervical cancer screening

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Why should people with HIV continue cervical cancer screening even after vaccination?

A

The vaccine does not prevent all HPV types and may be less effective in those with low CD4 counts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What type of condoms are recommended for preventing HPV transmission?

A

Male latex condoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What is the efficacy of consistent male condom use in women regarding oncogenic HPV infection?

A

Associated with 70% lower incidence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What is the association of consistent condom use among heterosexual men with no steady sex partner?

A

50% lower odds of HPV infection of the penis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What are the benefits of male condoms besides preventing HPV?

A

Reducing risk of nearly all STIs, including HIV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

What alternative should be considered when male condoms cannot be used properly?

A

Female condom (e.g., FC1 or FC2 Female Condom)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

How does male circumcision impact oncogenic HPV infection rates?

A

Reduces rates of oncogenic HPV infection of the penis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

What is the evidence regarding circumcision and HPV infection in people with HIV?

A

Effects may be less protective in people with HIV than in those without

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

What are the cervical cancer screening recommendations for people with HIV aged 21 to 29 years?

A

Cervical cytology at the time of initial diagnosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

What is the rationale for starting cervical cancer screening at age 21 for people with HIV?

A

To provide a 3- to 5-year window before age 25 when risk exceeds that of the general population

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

What should be done if cytology reveals ASC-US and reflex hr-HPV testing is positive?

A

Refer for colposcopy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

What is the recommendation for cervical cancer screening for people with HIV aged 30 years and older?

A

Continue screening throughout their lifetime

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

What types of tests are acceptable for cervical cancer screening in people with HIV aged 30 years and older?

A

Cytology only or cytology and HPV co-testing

38
Q

What is the absolute incidence of invasive cervical cancer (ICC) among women with HIV under 25 years?

A

Exceedingly low

39
Q

What are the possible cervical cytology results?

A
  • Normal (negative for intraepithelial lesion or malignancy) * LSIL or CIN 1 * HSIL or CIN 2, 3 * ASC-US * ASC-H * AGC
40
Q

What is the prevalence of positive HPV screening tests in women with HIV compared to the general population?

A

Several-fold more common

41
Q

What does primary oncogenic HPV screening aim to achieve?

A

Reduce unnecessary colposcopies

42
Q

What is the recommendation for patients with a history of high-grade CIN after hysterectomy?

A

Annual vaginal cuff cervical cytology

43
Q

What is the recommendation for screening for anal cancer in people with HIV?

A

Annual assessment of anal symptoms and screening for anal HSIL

44
Q

What should MSM and transgender women below the age of 35 undergo for anal cancer screening?

A

Digital anorectal examination (DARE) and standard anoscopy

45
Q

What is recommended for MSM and transgender women aged 35 and above with symptoms?

A

Refer to high-resolution anoscopy (HRA)

46
Q

What is the classification of VAIN?

A

Parallels that of the cervix: VAIN 1, VAIN 2, and VAIN 3

47
Q

What is the recommendation for vulvar cancer screening?

A

Biopsy or referral when lesions suspicious for VIN or cancer are identified

48
Q

What does the term ‘co-testing’ refer to?

A

Combined cytology and high-risk HPV (hr-HPV) testing

49
Q

What does ‘primary HPV testing’ refer to?

A

hr-HPV testing alone

50
Q

What does HRA stand for?

A

High-resolution anoscopy

HRA identifies anal HSIL and allows for treatment to prevent progression to anal cancer.

51
Q

What is the purpose of HRA?

A

Identifies anal HSIL and enables treatment to prevent progression to anal cancer

Requires biopsy for histopathologic confirmation.

52
Q

What is standard anoscopy?

A

Visualization of the anal canal and perianal region through an anoscope without application of 5% acetic acid or Lugol’s iodine

Used to identify lesions and rule out invasive cancer.

53
Q

What additional tools are used in HRA compared to standard anoscopy?

A

5% acetic acid and Lugol’s iodine

HRA allows greater precision in identifying flat lesions.

54
Q

At what age should MSM and transgender women with HIV begin screening for anal HSIL?

A

Age 35

This recommendation is based on the incidence of anal cancer.

55
Q

At what age should cisgender women and other persons with HIV begin screening for anal cancer?

A

Age 45

Screening guidelines vary based on sex and HIV risk group.

56
Q

What factors increase the risk of anal cancer in people with HIV?

A
  • Older age
  • Longer known duration of immune suppression and HIV infection
  • History of AIDS
  • Smoking
  • Positive HPV16 or 18 status
  • Higher grade of cytologic abnormality

Individuals meeting these criteria should be screened and referred for HRA.

57
Q

What screening methods can be used for anal cancer?

A
  • Anal cytology alone
  • hr-HPV co-testing

HRA and treatment should be available for effective screening.

58
Q

What are the recommendations regarding HPV testing in screening?

A

No FDA-cleared anal HPV tests are available; use only CLIA-certified laboratories

HPV testing should not be used for screening, diagnosis, or management of visible genital/oral warts.

59
Q

What is the recommendation from the International Anal Neoplasia Society regarding anal cancer screening for people with HIV?

A

Screen MSM and transgender women aged more than 35 years with HIV and all others aged 45 years or above with HIV

This aligns with NIH OAR guidelines.

60
Q

What is the treatment recommendation if HSIL is identified on biopsy?

A

Treatment of the lesion should be performed to reduce the incidence of anal cancer among people with HIV

This is classified as a strong recommendation (AI).

61
Q

What methods exist for diagnosing genital and oral warts?

A

Visual inspection and biopsy if uncertain

No data supports HPV testing for screening or management.

62
Q

What is the recommended treatment for uncomplicated external warts that can be easily identified by patients?

A
  • Topical imiquimod (5% cream)
  • Topical podofilox (0.5% solution or gel)
  • Topical sinecatechins (15% ointment)
  • Topical cidofovir (1%)

Each treatment has specific application instructions and duration.

63
Q

What are provider-applied treatment options for complex or multicentric lesions?

A
  • Cryotherapy
  • TCA and BCA
  • Intralesional cidofovir
  • Surgical treatments

Laser surgery is an option but is usually more expensive.

64
Q

What considerations should be made during pregnancy for treating warts?

A

Topical treatments and ablative therapies can be used

Obstetrical management should not change unless extensive condylomata might impede vaginal delivery.

65
Q

What are the key differences in cancer survival rates between people with HIV and the general population?

A

Cancer-specific survival following treatment of anal cancer and oropharyngeal cancer was similar; cervical cancer survival was lower in women with HIV

HIV is associated with higher risk of relapse and cervical cancer mortality.

66
Q

How do genital warts in people with HIV differ from those in immunocompetent individuals?

A

People with HIV may have larger or more numerous warts, may not respond as well to therapy, and may have more frequent recurrences after treatment.

67
Q

Are genital warts life-threatening?

A

No, genital warts are not life-threatening and may regress without therapy.

68
Q

What should be done for refractory lesions in people with HIV?

A

Histologic diagnosis should be obtained to confirm the absence of high-grade disease.

69
Q

What is the recommended treatment for uncomplicated external warts?

A

Patient-applied treatments are recommended.

70
Q

What is Imiquimod and how should it be applied?

A

Imiquimod (5% cream) is a topical cytokine inducer applied at bedtime on 3 nonconsecutive nights per week for up to 16 weeks.

71
Q

How should Podofilox be applied for genital warts?

A

Podofilox 0.5% solution or gel should be applied twice a day for 3 days, followed by 4 days of no therapy.

72
Q

What is the application frequency for sinecatechins?

A

Sinecatechins (15% ointment) should be applied three times daily for up to 16 weeks.

73
Q

What are provider-applied treatments for complex lesions?

A

Cryotherapy, trichloroacetic acid (TCA), bichloroacetic acid (BCA), and surgery.

74
Q

What is cryotherapy and how is it performed?

A

Cryotherapy destroys lesions by thermal-induced cytolysis, applied until each lesion is thoroughly frozen, repeated every 1 to 2 weeks.

75
Q

What is the action of TCA and BCA on warts?

A

Both act as caustic agents to destroy wart tissue.

76
Q

What is the recommended management for CIN in people with HIV?

A

Managed according to ASCCP guidelines.

77
Q

What treatments are available for biopsy-confirmed high-grade CIN?

A
  • Ablation (cryotherapy, laser vaporization, electrocautery) * Excisional methods (loop electrosurgical excision, laser conization, cold knife conization)
78
Q

What is the recommended follow-up for high-grade CIN in adolescents and young women?

A

Close observation should be considered due to higher progression and recurrence.

79
Q

What is the treatment approach for recurrent high-grade CIN?

A

Diagnostic excisional methods are recommended.

80
Q

What are the management guidelines for vulvar and vaginal cancer?

A

Must be individualized in consultation with a specialist, following NCCN guidelines.

81
Q

What is a reasonable first-line treatment for anal HSIL?

A

Office-based hyfrecation.

82
Q

What is the effect of early ART initiation on HPV-related disease?

A

Early ART initiation is clinically beneficial in reducing risk of AIDS and opportunistic infections.

83
Q

What are common adverse events following treatment for CIN?

A
  • Pain * Discomfort * Intraoperative hemorrhage * Postoperative hemorrhage * Infection * Cervical stenosis
84
Q

What should be monitored during treatment for genital warts?

A

Physical examination to detect toxicity, persistence, or recurrence.

85
Q

What treatment is recommended for recurrent genital warts?

A

Retreatment with any of the modalities previously described should be considered.

86
Q

What is the recommendation for monitoring after therapy for cervical disease?

A

Follow ASCCP guidelines.

87
Q

What is the recommendation for pregnant individuals with genital warts?

A

Managed by an interdisciplinary team of specialists.

88
Q

What treatments should not be used during pregnancy?

A

Podofilox should not be used.

89
Q

What is the presumed mechanism of juvenile-onset recurrent respiratory papillomatosis?

A

Transmission of genital HPV6 and 11 from vaginal secretions at delivery.

90
Q

What is the management recommendation for pregnant individuals with abnormal cervical cytology results?

A

Colposcopy and cervical biopsy of suspicious lesions.

91
Q

What is the recommendation regarding HPV vaccination during pregnancy?

A

HPV vaccination is not recommended during pregnancy.

92
Q

What should be done for suspected cervical cancer during pregnancy?

A

Refer to a gynecologic oncologist for definitive diagnosis and treatment.